Physician profile
Ryan E Denney
NPI 1437496197
$1,825.30
in general payments reported to CMS, 2019-2025
20 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.07 · 2020: $93.84 · 2021: $317 · 2022: $454 · 2023: $355 · 2024: $398 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.39 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $536.77 | 2021-2025 | Stelara, Simponi Aria, Remicade |
| Abbvie INC. | $481.52 | 2020-2025 | Mavyret |
| Merck Sharp & Dohme LLC | $171.97 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.46 | 2020-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $87.29 | 2022-2025 | Entyvio |
| Braintree Laboratories, INC. | $55.60 | 2020-2022 | |
| Csl Behring | $38.22 | 2023-2025 | Kcentra |
| Gilead Sciences, INC. | $37.60 | 2019-2022 | |
| Amgen INC. | $34.70 | 2021 | |
| Fresenius Kabi USA, LLC | $30.11 | 2023 | |
| Phathom Pharmaceuticals, INC. | $30.05 | 2024-2025 | Voquezna |
| Medtronic, INC. | $25.36 | 2022 | |
| Abbott Laboratories | $23.22 | 2022 | |
| Celgene Corporation | $21.35 | 2024 | Zeposia |
| Pfizer INC. | $20.40 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $18.44 | 2025 | Rezdiffra |
| Allergan, INC. | $17.84 | 2020 | |
| Intercept Pharmaceuticals, INC. | $17.43 | 2024 | |
| Dynavax Technologies Corporation | $15.11 | 2021 | |
| Phadia US INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.